Cargando…

The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events

AIMS: Guidelines do not recommend to take pattern of atrial fibrillation (AF) into account for the indication of anticoagulation (AC). We assessed AF pattern and the risk of cardiovascular events during 2-years of follow-up. METHODS AND RESULTS: We categorized AF as paroxysmal, persistent, or perman...

Descripción completa

Detalles Bibliográficos
Autores principales:	Atar, Dan, Berge, Eivind, Le Heuzey, Jean-Yves, Virdone, Saverio, Camm, A John, Steffel, Jan, Gibbs, Harry, Goldhaber, Samuel Z, Goto, Shinya, Kayani, Gloria, Misselwitz, Frank, Stepinska, Janina, Turpie, Alexander G G, Bassand, Jean-Pierre, Kakkar, Ajay K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005596/ https://www.ncbi.nlm.nih.gov/pubmed/31747004 http://dx.doi.org/10.1093/europace/euz292

Ejemplares similares

Guideline-directed medical therapies for comorbidities among patients with atrial fibrillation: results from GARFIELD-AF
por: Camm, Alan John, et al.
Publicado: (2023)

Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF registry
por: Fox, Keith A A, et al.
Publicado: (2022)

Comparative effectiveness of oral anticoagulants in everyday practice
por: Camm, A John, et al.
Publicado: (2021)

Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation – results from the GARFIELD-AF registry
por: Pope, Marita Knudsen, et al.
Publicado: (2021)

Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation
por: Camm, A John, et al.
Publicado: (2017)

Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD‐AF Registry
por: Cools, Frank, et al.
Publicado: (2021)

GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation
por: Fox, Keith A A, et al.
Publicado: (2021)

Determinants and clinical outcomes of patients who refused anticoagulation: findings from the global GARFIELD-AF registry
por: Apenteng, Patricia, et al.
Publicado: (2023)

Characteristics, treatment, and outcomes of newly diagnosed atrial fibrillation patients with heart failure: GARFIELD‐AF
por: Ambrosio, Giuseppe, et al.
Publicado: (2021)

Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation
por: Fox, Keith A. A., et al.
Publicado: (2020)

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation
por: Fox, Keith A A, et al.
Publicado: (2017)

Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry
por: Haas, Sylvia, et al.
Publicado: (2016)

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)
por: Beyer-Westendorf, Jan, et al.
Publicado: (2019)

Healthcare Resource Utilization in Patients with Newly Diagnosed Atrial Fibrillation: A Global Analysis from the GARFIELD-AF Registry
por: Mantovani, Lorenzo G., et al.
Publicado: (2023)

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF
por: Bassand, Jean-Pierre, et al.
Publicado: (2016)

Association of body mass index with outcomes in patients with newly diagnosed atrial fibrillation: GARFIELD-AF
por: Camm, Christian Fielder, et al.
Publicado: (2022)

New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF
por: Goto, Shinichi, et al.
Publicado: (2019)

Predictors of intracranial hemorrhage in patients with atrial fibrillation treated with oral anticoagulants: Insights from the GARFIELD‐AF and ORBIT‐AF registries
por: Lim, Toon Wei, et al.
Publicado: (2023)

Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry
por: Kakkar, Ajay K., et al.
Publicado: (2013)

Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry
por: Goto, Shinya, et al.
Publicado: (2019)

Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry
por: Camm, A John, et al.
Publicado: (2017)

On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease
por: Haas, Sylvia, et al.
Publicado: (2022)

Rhythm versus rate control in patients with newly diagnosed atrial fibrillation – Observations from the GARFIELD-AF registry
por: Knudsen Pope, Marita, et al.
Publicado: (2023)

Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation
por: Bassand, Jean-Pierre, et al.
Publicado: (2018)

Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD‐VTE
por: Cohen, Omri, et al.
Publicado: (2021)

Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease
por: Goto, Shinya, et al.
Publicado: (2020)

Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE
por: Ageno, Walter, et al.
Publicado: (2021)

Two-year outcomes of UK patients newly diagnosed with atrial fibrillation: findings from the prospective observational cohort study GARFIELD-AF
por: Apenteng, Patricia N, et al.
Publicado: (2022)

Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial
por: Cools, Frank, et al.
Publicado: (2022)

Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents
por: Bassand, Jean-Pierre
Publicado: (2012)

Universal Clinician Device for improving risk prediction and management of patients with atrial fibrillation: an assumed benefit analysis
por: van Husen, Georg, et al.
Publicado: (2022)

Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE
por: Jerjes-Sánchez, Carlos, et al.
Publicado: (2021)

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
por: Kirchhof, Paulus, et al.
Publicado: (2020)

Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism
por: Turpie, Alexander G.G.
Publicado: (2012)

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
por: Turpie, Alexander GG
Publicado: (2014)

Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment
por: Turpie, Alexander G.G., et al.
Publicado: (2017)

Non-vitamin K antagonist oral anticoagulants therapy for atrial fibrillation patients undergoing electrophysiologic procedures
por: Steffel, Jan
Publicado: (2020)

Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry
por: Papp, Judit, et al.
Publicado: (2017)

Right heart perforation by pacemaker leads
por: Banaszewski, Marek, et al.
Publicado: (2012)

Optimization of DOAC management services in a centralized anticoagulation clinic
por: Sylvester, Katelyn W., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m8bn2c9veu0gs2j1a63cqiml3k